INHIBITORY EFFECT OF DEXAMETHASONE AND PROGESTERONE IN-VITRO ON PROLIFERATION OF HUMAN RENAL-CELL CARCINOMAS AND EFFECTS ON EXPRESSION OF INTERLEUKIN-6 OR INTERLEUKIN-6 RECEPTOR

Citation
J. Takenawa et al., INHIBITORY EFFECT OF DEXAMETHASONE AND PROGESTERONE IN-VITRO ON PROLIFERATION OF HUMAN RENAL-CELL CARCINOMAS AND EFFECTS ON EXPRESSION OF INTERLEUKIN-6 OR INTERLEUKIN-6 RECEPTOR, The Journal of urology, 153(3), 1995, pp. 858-862
Citations number
20
Categorie Soggetti
Urology & Nephrology
Journal title
ISSN journal
00225347
Volume
153
Issue
3
Year of publication
1995
Part
1
Pages
858 - 862
Database
ISI
SICI code
0022-5347(1995)153:3<858:IEODAP>2.0.ZU;2-B
Abstract
Interleukin-6 (IL-6) has been suggested as an autocrine growth factor of human renal cell carcinomas. Since steroids are known to inhibit IL -6 gene expression, we investigated their effects on the growth of ren al cell carcinoma. Dexamethasone inhibited proliferation of 2 of 4 ren al cell carcinoma cell lines in a dose-dependent manner. In one of the se 2 cell lines, IL-6 gene expression was also inhibited, but not in t he other. The inhibitory effect of dexamethasone on cell proliferation was not reversed by the exogenous IL-6. In 1 of the 2 remaining cell lines, the inhibition of IL-6 gene expression was observed, although t here was no inhibition of cell proliferation. Thus, inhibition of grow th by dexamethasone did not correlate with an inhibitory action of dex amethasone on IL-6 mRNA expression. Progesterone inhibited the growth of 1 cell line without concomitant inhibition of IL-6 gene expression. Expression of IL-6 receptor mRNA was not altered. A dose-dependent in crease in mRNA expression of gp130, the transducer of IL-6 signal, was induced by dexamethasone and progesterone in 2 and 1 of the 4 cell li nes, respectively. These data suggest that, in some renal cell carcino mas, steroids may inhibit cell proliferation by a mechanism independen t of their effects on mRNA expression of IL-6 and IL-6 receptors. Dexa methasone may be useful, not only for palliation of paraneoplastic syn drome caused by overproduction of IL-6, but also for inhibition of gro wth of renal cell carcinomas.